Cannara Biotech Inc.
Cannara Biotech Inc. (LOVE.V) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
love.v · pe ratio · data through Aug 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cannara Biotech Inc. (LOVE.V) measures how much investors pay for each dollar of the company's trailing earnings. LOVE.V's current PE ratio of 13.33x is calculated by dividing its stock price of $1.89 by its TTM earnings per share of $0.13. −38.4% discount vs 5Y avg 21.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-08-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%12.9x
MedianQ3 · 75%51.3x
Max
At 13.33x, LOVE.V's current P/E is higher than in 75% of its annual fiscal year readings over the past 4 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cannara Biotech Inc.You LOVE.V | $181M | 13.33x | — | $0.13 |
 Cardiol Therapeutics Inc. CRDL.TO | $173M | N/A | — | -$0.39 |
 Decibel Cannabis Company Inc. DB.V | $66M | N/A | — | -$0.01 |
 Grown Rogue International Inc. GRIN.CN | $160M | 16.92x | — | $0.03 |
 Helix BioPharma Corp. HBP.TO | $117M | N/A | — | -$0.09 |
 HLS Therapeutics Inc. HLS.TO | $138M | N/A | — | -$0.40 |
 Jushi Holdings Inc. JUSH.CN | $144M | N/A | — | -$0.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-08-31Latest FY2025 | 12.86x | $0.14 | +35.2% | |
2024-08-31 FY2024 | 9.51x | $0.07 | -26.0% | |
2023-08-31 FY2023 | 12.86x | $0.08 | -75.0% | |
2022-08-31 FY2022 | 51.34x | $0.03 | — | |
2021-08-31 FY2021 | — | $-0.04 | — | |
2020-08-31 FY2020 | — | $-0.19 | — | |
2019-08-31 FY2019 | — | $-0.20 | — | |
2018-08-31 FY2018 | — | $-0.03 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cannara Biotech Inc. (LOVE.V) measures how much investors pay for each dollar of the company's trailing earnings. LOVE.V's current PE ratio of 13.33x is calculated by dividing its stock price of $1.89 by its TTM earnings per share of $0.13.
Frequently asked questions
LOVE.V pe ratio · 6 questionsLOVE.V's current PE ratio is 13.33x as of 2026-06-08, based on a stock price of $1.89 and TTM EPS of $0.13. Data sourced from Financial Modeling Prep via LOVE.V's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cannara Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08